DIASORIN SPA ENTERS INTO A PRODUCT DEVELOPMENT AND DISTRIBUTION AGREEMENT WITH MERIDIAN INC.

This agreement just signed with Meridian will further consolidate DiaSorin well known leadership in infectious diseases.

Saluggia (Italy) July the 7th 2010. DiaSorin S.p.A. today announced that it has entered into an exclusive, world-wide product development and distribution agreement with Meridian Inc. Under terms of the agreement, DiaSorin will utilize key Meridian technology to develop a gastrointestinal panel for use on LIAISON® and LIAISON XL®, the proprietary fully automated, random access systems based on chemiluminescence detection. The agreement is royalty-based with the actual royalty amount to be paid to Meridian dependent on type of test and specific geographic market.

DiaSorin has been rapidly expanding the product menu for the LIAISON® system and today can offer 85 tests out of which 36 considered speciality test, with a strong focus on infectious diseases. Thanks to this agreement with Meridian, and leveraging on the LIAISON installed base of more than 3,100 instruments, DiaSorin will further strengthen its well recognized leadership in infectious diseases; in fact, under the terms of the agreement DiaSorin will have exclusive distribution rights for the developed products in every geographic market except the United States and United Kingdom, where Meridian will retain the option for distribution. The first two products to be developed will be for the detection of Clostridium difficile, a leading hospital acquired infection, and Helicobacter pylori, the leading cause of stomach ulcers and a recognized contributor to gastric cancer, whose market potential is globally estimated to exceed 100 Million Dollars.
Carlo Rosa, Chief Executive Officer of DiaSorin, stated “We are sincerely happy with this agreement that will give us the opportunity to partner with Meridian, a leading company in GI tract infections. More than 3,100 LIAISON platforms installed worldwide, covering almost all geographical areas, combined with a menu enriched by high quality tests developed with Meridian will definitely enable our Group to underscore, even more unequivocally, its position as a specialist in the area of infectious diseases”.

About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 20 companies based in Europe, the United States, Central and South America and Asia. It has more than 1,100 employees, including about 110 research and development specialists, and operates four manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA) and Dublin (Ireland). Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which it operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: www.diasorin.it

Contacts:

Investor Relations Officer
Laura Villa
DiaSorin S.p.A.
laura.villa@diasorin.it
+39 02 9647 4567
+39 348 15 11 542

Press Office
Carolina Mailander
c.mailander@mailander.it
+39 335 655 56 51
Bruno Caprioli
caprioli@mailander.it
+39 335 590 14 02